在患有外周动脉疾病的患者中使用帕克利塔塞尔涂层设备后的结果:全国人口研究
Chen-Yu Huang1, Jen-Kuang Lee2, Hsu-Ping Wu3
1Cardiovascular Centre, Cathay General Hospital, Taipei, Taiwan.
概括
在外周动脉疾病重血管化中,用帕克利塔塞尔涂层设备 (PCD) 与较低的死亡率和心血管风险有关. 肢体结果显示没有显著差异,这挑战了先前的元分析结果.
科学领域:
- 血管外科 血管外科
- 干预心脏病学 干预心脏病学
- 健康 结果 研究 研究 结果
背景情况:
- 之前的元分析表明,在外周动脉疾病 (PAD) 复血管化后一年内,用帕克利塔塞尔涂层器件 (PCD) 增加死亡率.
- 这些发现引起了争议,需要进一步进行现实世界的安全评估.
研究的目的:
- 在接受内血管下肢再血管化的患者中对PCD进行真实世界的安全分析.
- 调查PCD使用与死亡率,肢体结果和心血管结果之间的关联.
主要方法:
- 一项全国性的回顾性队列研究利用了来自台湾国家健康保险研究数据库的行政医疗数据.
- 分析了2016年5月至2019年12月期间接受了内血管下肢再血管化的19,612名患者.
- 倾向性得分匹配被用来比较接受PCD和非PCD患者之间的结果.
主要成果:
- 超过14.2个月的中位数,接受PCD的患者与非PCD相比,所有原因死亡的风险较低 (sHR 0.71).
- 复合心血管结局在PCD组 (20.1%) 与非PCD组 (23.3%) (sHR 0.79) 相比较少.
- 在PCD和非PCD组之间的复合四肢结果中没有发现显著差异 (sHR 0.98).
结论:
- 在内血管再血管化中使用的帕克利塔塞尔涂层器件 (PCD) 与所有死因死亡风险的降低有关.
- 使用PCD与较低的复合心血管结局风险有关.
- 在PCD和非PCD组之间,复合四肢结果没有明显的差异.
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
145
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
145
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
131
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
131